Skip to main content

MedCity and The Mission Fund have partnered to find and finance early-stage biotechs requiring evidence generation for a groundbreaking curative therapy. Up to £500k will be invested per company.


Who is Eligible?

We are looking for early-stage biotech companies with a groundbreaking research proposal in one of three therapeutic areas: solid tumours, mental health, healthy ageing.

To be eligible for investment you should:

  • be developing a breakthrough curative therapy in solid tumours, mental health or healthy ageing

  • be a company with shares registered in the UK or Europe

  • have market capitalisation of less than £6 million

  • have potential to develop a patented product that is scalable and affordable (for UK & European markets)

What Is The Mission Fund?

The Mission Fund is a new venture fund, founded by Alex Blyth, founder and CEO of LIfT BioSciences, and launched in partnership with MedCity and early-stage investment specialists Oxford Technology Management.

With the aim of accelerating the development of curative therapies to reach patients sooner, the fund will help start-ups generate critical evidence faster, enabling them to attract further investment.

A world-class Scientific Review Board, with representatives from leading global pharma companies, academia and high-quality venture capital, is working with the fund to evaluate the candidate companies and provide strategic advice and guidance.



How Do I Apply?


Attach your pitch deck to the application using the template supplied (link below)

Applications open on 1st November and close on 6th December. Shortlisted companies will be notified and invited to an interview.

We will be running a live Q&A session which you are welcome to attend with any queries. Please check back here for registration details.

The 2022 Investment Call is Supported By:

Contact us